Search results for "Guidelines"

showing 10 items of 617 documents

Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway pr…

2020

Background and aims: Post-acute coronary syndrome (ACS) patients are at very high risk for recurrent events and mortality, despite the availability of effective pharmacological approaches. Aim of this survey was to evaluate the compliance to ESC/EAS guidelines during the management of ACS patients and the effectiveness of secondary prevention in seven European countries.Methods: By means of an online questionnaire, data on 2775 ACS patients (either acute case or follow-up patients) were collected, including data on lipid profile, medications, follow-up visit planning, screening for familial hypercholesterolemia.Results: Lipid profiles were obtained for 91% of ACS patients in the acute phase…

MaleAcute coronary syndromemedicine.medical_specialtyLow density lipoprotein cholesterolFamilial hypercholesterolemia030204 cardiovascular system & hematologyGuidelinesPatient pathwayLipid-lowering therapy03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicinemedicineGoal achievementHumansIn patientLow-density lipoprotein cholesterol030212 general & internal medicineAgedmedicine.diagnostic_testbusiness.industryAnticholesteremic AgentsStatinsDisease ManagementGeneral MedicineCholesterol LDLLipid-lowering therapiesmedicine.diseaseFemaleAcute coronary syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicineLipid profilebusinessGoals
researchProduct

Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study

2018

AbstractPatients with heart failure (HF) are frequently anti-coagulated with vitamin K-antagonists (VKAs). The use of long-acting VKA may be preferable for HF patients due to higher stability of plasma concentrations. However, evidence on phenprocoumon-based oral anti-coagulation (OAC) therapy in HF is scarce. The aim of this study was to assess the impact of the presence of HF on quality of phenprocoumon-based OAC and the subsequent clinical outcome. Quality of OAC therapy and the incidence of adverse events were analysed in a cohort of regular care (n = 2,011) from the multi-centre thrombEVAL study program (NCT01809015) stratified by the presence of HF. To assess the modifiability of outc…

MaleAdministration Oralheart failureclinical outcomeED AMERICAN-COLLEGE030204 cardiovascular system & hematologyTHERAPY ANTITHROMBOTIC THERAPYCohort StudiesPhenprocoumon0302 clinical medicinequality of careGermanyProspective Studies030212 general & internal medicineProspective cohort studyAged 80 and overOUTCOMESIncidenceHazard ratioHematologyTreatment OutcomeCohortFemaleCLINICAL-PRACTICE GUIDELINESSINUS RHYTHMmedicine.drugCohort studyRiskmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHemorrhageWARFARINEJECTION FRACTION03 medical and health sciencesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryWarfarinhealth care modelAnticoagulantsmedicine.diseaseoral anti-coagulationHeart failureATRIAL-FIBRILLATIONPhenprocoumonADVERSE EVENTSbusinessANTICOAGULANT-THERAPY
researchProduct

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Ita…

2021

Nonalcoholic fatty liver disease (NAFLD) is a common and emerging liver disease in adults, paralleling the epidemic of obesity and diabetes, and leading to worrisome events (hepatocellular carcinoma and end-stage liver disease). In the last years, mounting evidence added insights about epidemiology, natural history, diagnosis and lifestyle-based or drug treatment of NAFLD. In this rapidly evolving scenario, members of the Associazione Italiana per lo Studio del Fegato (AISF), the Società Italiana di Diabetologia (SID) and the Società Italiana dell'Obesità (SIO) reviewed current knowledge on NAFLD. The quality of the published evidence is graded, and practical recommendations are made follow…

MaleAdultEndocrinology Diabetes and MetabolismSettore MED/12 - GASTROENTEROLOGIAMedicine (miscellaneous)Settore MED/09GuidelineGuidelinesGuidelines NAFLD NASHNon-alcoholic Fatty Liver DiseaseMedicalNAFLDHumansObesitySocieties MedicalPatient Care TeamNutrition and DieteticsGuidelines; NAFLD; NASH; Adult; Delivery of Health Care; Humans; Obesity; Non-alcoholic Fatty Liver Disease; Sudden Infant DeathHepatologyGastroenterologyNASHDisease ManagementGuidelines; NAFLD; NASH; Adult; Delivery of Health Care; Female; Humans; Italy; Male; Patient Care Team; Societies Medical; Disease Management; Non-alcoholic Fatty Liver DiseasePsychiatry and Mental healthClinical PsychologyItalyGuidelines; NAFLD; NASHFemaleCardiology and Cardiovascular MedicineSocietiesDelivery of Health CareSudden Infant DeathHumanEating and weight disorders : EWD
researchProduct

The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update

2018

Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline up…

MaleAftercare32 Biomedical and Clinical SciencesLanadelumabC1-inhibitorDiseaseGuidelineRecommendations0302 clinical medicinePregnancyDiagnosisImmunology and Allergy030212 general & internal medicinePrecision MedicineChildHereditary angioedemaConsensus conferenceSelf-administrationManagementGRADEHereditary angioedemaFemaleComplement C1 Inhibitor ProteinQuality of lifeAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyWhat treatmentConsensusAdolescentHealth Planning GuidelinesImmunologyMEDLINEDysfunctional family7.3 Management and decision makingYoung Adult03 medical and health sciencesRare DiseasesQuality of life (healthcare)Clinical ResearchTerminology as TopicIndividualized therapymedicineHumansLactationFinal versionProphylaxisbusiness.industryPreventionAngioedemas HereditaryGuidelinePrecision medicinemedicine.disease3211 Oncology and Carcinogenesis030228 respiratory systemFamily medicineTherapybusiness7 Management of diseases and conditions
researchProduct

Global, regional, and national burden of stroke and its risk factors, 1990–2019 : a systematic analysis for the Global Burden of Disease Study 2019

2021

Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]…

MaleAging030204 cardiovascular system & hematologyStroke dataGUIDELINES3124 Neurology and psychiatryBody Mass IndexGlobal Burden of Disease0302 clinical medicineRA0421Risk FactorsEpidemiologyStrokesYOUNG-ADULTSPrevalence80 and overAetiology610 Medicine & healthStrokePOPULATION1103 Clinical Sciences 1109 NeurosciencesCause of deathAged 80 and overeducation.field_of_studyMortality rateIncidence (epidemiology)Incidence1. No povertyArticlesHälsovetenskaperMiddle AgedStroke typesddc:3. Good healthStrokeISCHEMIC-STROKEIncomeFemaleQuality-Adjusted Life YearsLife Sciences & BiomedicineAdultmedicine.medical_specialtyGBDPopulationClinical SciencesClinical Neurology610 Medicine & health03 medical and health sciencesClinical ResearchMIDDLE-INCOME COUNTRIESHealth SciencesmedicineHumansRisk factoreducationGBD 2019 Stroke CollaboratorsCerebral HemorrhageAgedIschemic StrokeGlobal burdenScience & TechnologyNeurology & NeurosurgeryHYPERTENSIONbusiness.industryMORTALITYPrevention3112 NeurosciencesNeurosciences1103 Clinical SciencesSERVICESSubarachnoid Hemorrhagemedicine.diseasePREVENTIONBrain DisordersGood Health and Well BeingAttributable riskHuman medicineNeurology (clinical)Neurosciences & Neurologybusiness1109 Neurosciences030217 neurology & neurosurgeryDemography2.4 Surveillance and distributionRC
researchProduct

From Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines to Current Clinical Practice

2006

Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines have been promulgated to improve the management of chronic obstructive pulmonary disorder (COPD). Objective: To evaluate the extent to which the current therapeutic approach to COPD conforms to GOLD guidelines. Methods: This was a multicentre observational study of elderly COPD patients enrolled for acute care in general medicine or geriatric wards in tertiary hospitals in Italy in April 2002. Our series consisted of 471 patients >64 years of age consecutively admitted for acute exacerbations of COPD to wards participating in the study. Data describing drugs used prior to exacerbation and prescribed at …

MaleAgingmedicine.medical_specialtyDrug IndustryPharmacological therapyGuidelines as Topicurologic and male genital diseasesPulmonary Disease Chronic ObstructivePharmacotherapyOdds RatiomedicineHumansMulticenter Studies as TopicPharmacology (medical)Practice Patterns Physicians'Intensive care medicineAgedCOPDbusiness.industryRespiratory diseaseTiotropium bromidemedicine.diseaseDrug UtilizationObstructive lung diseaserespiratory tract diseasesClinical PracticeLung diseasePhysical therapyFemaleGuideline AdherenceAcute Exacerbation Tiotropium Methylxanthine Tiotropium Bromide Cumulative Illness Rate ScaleGeriatrics and Gerontologybusinessmedicine.drugDrugs & Aging
researchProduct

Analysis of polymorphisms Leiden Factor V G1691A and prothrombin G20210A as risk factors for acute myocardial infarction.

2011

Thrombotic risk increases in elderly, therefore, the understanding of the genetic predisposition of hypercoagulability could make the difference in the prevention of venous and/or arterial thrombotic events. Laboratory evaluation of hyperfibrinogenemia, increased Factor VII levels, antiphospholipid antibodies presence and hyperhomocysteinemia are considered to have a consistent high predictivity for arterial thrombophilic diseases. Anyway, a large debate exists on the validity of testing Leiden Factor V (FV) G1691A and/or prothrombin (FII) G20210A polymorphisms in patients affected by arterial thrombotic diseases, despite of the several observations described. Here we report data strongly s…

MaleAgingmedicine.medical_specialtyHyperhomocysteinemiaLeiden Factor V; Prothrombin; Stroke; Guidelines; Arterial thrombosis.Myocardial InfarctionHyperfibrinogenemiaGuidelineGUIDELINESGastroenterologyCohort Studieschemistry.chemical_compoundInternal medicineArterial DisorderGenotypeGenetic predispositionmedicineHumansGenetic Predisposition to DiseaseMyocardial infarctionAgedAged 80 and overPolymorphism GeneticFactor VIIbusiness.industryFactor VMiddle Agedmedicine.diseaseSurgeryStrokeTHROMBOSISchemistryArterial thrombosis.Prothrombin G20210AFemaleProthrombinGeriatrics and GerontologybusinessGerontologyLeiden Factor V
researchProduct

Management of anaphylaxis due to COVID-19 vaccines in the elderly

2021

Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffab…

MaleAllergyPediatricsEaaci Position PaperCOVID-19 vaccinesolder (adultsGUIDELINES0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesMedicine and Health SciencesImmunology and AllergyMedicine030212 general & internal medicineComputingMilieux_MISCELLANEOUSGeriatricsMESH: AgedRISKVaccines[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasespeople)EPINEPHRINEEpinephrine[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCOVID -19 vaccinesAnaphylaxismedicine.drugolder (adults/people)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)MESH: Covid-19MESH: EpinephrineImmunologyadrenaline; anaphylaxis; COVID-19 vaccines; older (adults/people); Aged; COVID-19 Vaccines; Epinephrine; Humans; Male; SARS-CoV-2; Anaphylaxis; COVID-19Settore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemDiabetes mellitusAnaphylaxis/etiologyanaphylaxisHumansMESH: SARS-CoV-2[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyCOVID‐19 vaccinesOlder - Adults/peopleAsthmaAgedMESH: Humansadrenalinebusiness.industrySARS-CoV-2adrenaline anaphylaxis COVID-19 vaccines older (adults/people)COVID-19medicine.diseaseObesity[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyMESH: MaleMESH: AnaphylaxisOlder3121 General medicine internal medicine and other clinical medicinebusinessMESH: Covid-19 vaccines030215 immunologyAllergy
researchProduct

Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia.

2015

none 22 no Background: Few studies evaluated the clinical outcomes of Community Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia (HAP) and Health Care-Associated Pneumonia (HCAP) in relation to the adherence of antibiotic treatment to the guidelines of the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) in hospitalized elderly people (65 years or older). Methods: Data were obtained from REPOSI, a prospective registry held in 87 Italian internal medicine and geriatric wards. Patients with a diagnosis of pneumonia (ICD-9 480-487) or prescribed with an antibiotic for pneumonia as indication were selected. The empirical antibiotic regimen was defined t…

MaleAntibiotic regimenGuidelines adherenceSettore MED/09 - Medicina InternaAntibioticsLogistic regressionElderlyCommunity-acquired pneumoniaAntibiotics80 and overElderly peopleAge FactorHospital MortalityAged 80 and overTreatment regimenMedicine (all)Age FactorsOptimal managementAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalization; Age Factors; Aged; Aged 80 and over; Anti-Bacterial Agents; Female; Hospital Mortality; Humans; Logistic Models; Male; Pneumonia; Practice Guidelines as Topic; Treatment Outcome; Guideline Adherence; Hospitalization; Internal Medicine; Medicine (all)Anti-Bacterial AgentsHospitalizationTreatment OutcomePractice Guidelines as TopicFemaleGuideline AdherenceHumanmedicine.medical_specialtyLogistic Modelmedicine.drug_classSocio-culturaleantibiotic treatment; guidelines; pneumonia; elderly;Internal medicineRe-hospitalizationAnti-Bacterial AgentmedicineInternal MedicineHumanselderly pmeumonia antibiotics guidelines adherence mortality re-hospitalizationpmeumoniaMortalityIntensive care medicineAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalization; Age Factors; Aged; Aged 80 and over; Anti-Bacterial Agents; Female; Hospital Mortality; Humans; Logistic Models; Male; Pneumonia; Practice Guidelines as Topic; Treatment Outcome; Guideline Adherence; Hospitalization; Internal MedicineAgedbusiness.industrySettore MED/09 - MEDICINA INTERNAAntibioticPneumoniamedicine.diseasePneumoniaAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalizationLogistic ModelsAntibiotics; Elderly; Guidelines adherence; Mortality; Pneumonia; Re-hospitalization; Age Factors; Aged; Aged 80 and over; Anti-Bacterial Agents; Female; Hospital Mortality; Humans; Logistic Models; Male; Pneumonia; Practice Guidelines as Topic; Treatment Outcome; Guideline Adherence; Hospitalizationbusiness
researchProduct

Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics

2018

Abstract Background Acute asthma attack is a frequent condition in children. It is one of the most common reasons for emergency department (ED) visit and hospitalization. Appropriate care is fundamental, considering both the high prevalence of asthma in children, and its life-threatening risks. Italian Society of Pediatrics recently issued a guideline on the management of acute asthma attack in children over age 2, in ambulatory and emergency department settings. Methods The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was adopted. A literature search was performed using the Cochrane Library and Medline/PubMed databases, retrieving studies in Englis…

MaleAsthma; Asthma attack; Children; GuidelinesPediatricsReviewGuidelineCochrane LibraryIpratropium bromidePediatricsSeverity of Illness Index0302 clinical medicineAnti-Asthmatic AgentsChildChildrenSocieties MedicalPediatriclcsh:RJ1-570PrognosisBronchodilator AgentsEpinephrineTreatment OutcomeInhalationItalyChild PreschoolAmbulatoryAdministrationCombinationPractice Guidelines as TopicDrug Therapy CombinationFemaleHumanmedicine.drugmedicine.medical_specialtyAdolescentPrognosiAsthma attackMEDLINEGuidelinesRisk Assessment03 medical and health sciencesDrug Therapy030225 pediatricsMedicalAdministration InhalationmedicineAnti-Asthmatic AgentHumansAsthma; Asthma attack; Children; Guidelines; Administration Inhalation; Adolescent; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Italy; Male; Pediatrics; Prognosis; Risk Assessment; Severity of Illness Index; Societies Medical; Treatment Outcome; Practice Guidelines as TopicPreschoolBronchodilator AgentAsthmabusiness.industrylcsh:PediatricsEmergency departmentGuidelinemedicine.diseaseAsthma030228 respiratory systemPediatrics Perinatology and Child HealthbusinessSocieties
researchProduct